Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
- Written by PR Newswire
![]() |
KYOTO, Japan, May 28, 2024 /PRNewswire/ -- Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en)has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014....















